Welcome to our dedicated page for SELLAS Life Sciences Group news (Ticker: $SLS), a resource for investors and traders seeking the latest updates and insights on SELLAS Life Sciences Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SELLAS Life Sciences Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SELLAS Life Sciences Group's position in the market.
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) announces positive Phase 1 data for SLS009 in AML patients, achieving complete remission with CDK9 inhibition monotherapy. Key objectives met with durable responses and favorable safety profile. Phase 2a data expected in March and Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
-
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. announces a change in the presentation date for data from the acute myeloid leukemia cohort in the Phase 1 study of SLS009 at the 2024 ESH Conference. The presentation will now take place on March 1, 2024, at 12:55 pm CEST in Stockholm, Sweden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announces a publication in Oncotarget revealing the underlying mechanisms of action behind the anti-proliferative effects of SLS009, its potent CDK9 small molecule inhibitor, in various hematologic malignancies. The research provides a robust pharmacodynamic and mechanistic foundation for the antiproliferative effects of SLS009 in hematologic cancers and shows its potential in tumor growth inhibition with a dose-dependent induction of apoptosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.48%
Tags
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announces the presentation of data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 at the 2024 ESH Conference. The presentation will be given by Dr. Tapan Kadia, detailing the Phase 1 Dose-Escalation Study of GFH009 in Acute Myeloid Leukemia. The session will take place on Sunday, March 3, 2024, at 12 pm CET in Stockholm, Sweden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
-
Rhea-AI Summary
GenFleet Therapeutics (GFH), a clinical-stage biotechnology company, received fast track and orphan drug designations from the FDA for its highly selective CDK9 inhibitor, GFH009, for the treatment of relapsed/refractory peripheral T-cell lymphomas (PTCL) and acute myeloid leukemia (AML). The company is conducting phase II studies for both indications, with positive clinical responses observed in previous studies. GenFleet's partner, Sellas Life Sciences, is also undertaking a phase II trial for GFH009 in combination with other drugs for treating r/r AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
-
Rhea-AI Summary
SELLAS Life Sciences Group, ticker symbol SLS, announced the completion of Phase 2a enrollment for SLS009, a CDK9 inhibitor, in patients with relapsed/refractory acute myeloid leukemia (AML). The Fast Track Designation from the FDA underscores the potential of SLS009, with positive topline Phase 2a data showing significant anti-leukemic effects and an 89% survival rate in the 45 mg dose cohort. The company aims to deliver a potentially groundbreaking treatment to AML patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced the pricing of a public offering for the purchase and sale of 12,000,000 shares of common stock and accompanying warrants, resulting in total gross proceeds of $9.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.26%
Tags
-
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced a public offering of shares of its common stock and warrants to purchase shares of common stock. The net proceeds will be used for funding ongoing operations, clinical development of existing product candidates, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.26%
Tags
-
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) will host a corporate update webinar to discuss the positive clinical progress and upcoming milestones for their cancer therapy programs, Galinpepimut-S (GPS) and SLS009.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced positive follow-up clinical/immune-response data from a Phase 1 trial of galinpepimut-S (GPS) combined with nivolumab in patients with relapsed malignant pleural mesothelioma. The study showed a 70.3 weeks median overall survival, a 208.3% increase in survival time for patients with GPS-specific immune response, and a 30% disease control rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
SELLAS Life Sciences Group, Inc.
Nasdaq:SLS
SLS Rankings
SLS Stock Data
84.32M
55.63M
0.5%
10.45%
9.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
NEW YORK
About SLS
σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.